Form 4 for AVIR Atea Pharmaceuticals, Inc.
Accepted 2025-02-04 00:00:00 ET · period of report 2025-01-31 · accession 0000950170-25-013846 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-04 | 2025-01-31 | AVIR | Sommadossi Jean-Pierre | Pres, CEO, COB, Dir | A - Grant | — | +99.5K | 389.5K | +34% | — |
| D | 2025-02-04 | 2025-01-31 | AVIR | Sommadossi Jean-Pierre | Pres, CEO, COB, Dir | M - OptEx | — | +173.5K | 290.0K | +149% | — |
| D | 2025-02-04 | 2025-01-31 | AVIR | Sommadossi Jean-Pierre | Pres, CEO, COB, Dir | F - Tax | $3.06 | -88.6K | 300.9K | -23% | -$271.1K |
| DM | 2025-02-04 | 2025-01-31 | AVIR | Sommadossi Jean-Pierre | Pres, CEO, COB, Dir | A - Grant | $0.00 | +539.5K | 99.5K | New | $0 |
| D | 2025-02-04 | 2025-01-31 | AVIR | Sommadossi Jean-Pierre | Pres, CEO, COB, Dir | M - OptEx | $0.00 | -173.5K | 173.5K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-31 | A | A | 99,517 | — | 389,541 | D | — | — | (F2) Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs"). |
| 2 | Common | Common Stock | 2025-01-31 | M | A | 173,467 | — | 290,024 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| 3 | Common | Common Stock | 2025-01-31 | F | D | 88,601 | $3.06 | 300,940 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2025-01-31 | A | A | 440,000 | $0.00 | 440,000 | D | $3.06 · — to 2035-01-30 | 440,000 Common Stock | (F5) The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029. |
| 5 | Derivative | Restricted Stock Units | 2025-01-31 | A | A | 99,518 | $0.00 | 99,518 | D | — · — to — | 99,518 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F4) Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer. |
| 6 | Derivative | Restricted Stock Units | 2025-01-31 | M | D | 173,467 | $0.00 | 173,466 | D | — · — to — | 173,467 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F3) The original grant of 520,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. |